Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.